Vital Neuro, a cloud-based, neuroscience-linked stress reduction service, has announced the launch of its Neuros Token Security Token Sale. The token sale pioneers the world’s first neurotechnology ICO with a preferred equity reward, granting token holders preferred equity in the company. Goldman Advisors Group will act as a consultant on this Initial Coin Offering.
A Neurotechnology-Based ICO With A Preferred Equity Reward
A subsidiary of Vital Neuro, Neuro Token has begun its global ICO, offering its Neuros Tokens to accredited investors. The ICO was initiated on its partner Start Engine’s website.
Vital Neuro’s token holders will be rewarded with preferred equity in the company, in accordance with its Simple Agreements for Future Equity (SAFE). This will be comprised of three offerings that adhere to Rule 506 (c) of Regulation D of the Securities Act.
Vital Neuro had raised $675,000 in a non-preferred private offering before this preferred equity offering.
Q Saeed, the Vital Neuro CEO has stated his contentment in Vital Neuro’s spearheading the nexus of neurotechnology and the cryptocurrency space.
The CEO said:
“Vital Neuro is proud to be the neurotechnology leading enterprise to embrace the crypto revolution. Vital Neuro today opens the Neuros Token ICO. Beginning with the ‘Pre-Sale Offering 1’ round, I am confident that accredited investors from around the globe will recognize the value and potential of our pioneering stress reduction service for companies, tapping a $250 Billion + global opportunity in the neuroscience market. We believe the market Vital is defining and segmenting will transform into a worldwide service for any human experiencing stress.”
The ICO Process & The Token Launch
The duration of September 14, 2018 – October 31, 2018 marks first offering of the Vital Neuro pre-sale. In the course of this pre-sale, Vital Neuro will enter into SAFEs with accredited investors. They will receive a 70% discount at the price of $1.50 per token and there will be a total of 7,000,000 issuable tokens.
Commencing on October 31, 2018 and running through December 31, 2018 is the second offering of the pre-sale. During this pre-sale, Vital neuro will enter into SAFEs with accredited investors for a 40% discount at the price of $3.00 per token. This pre-sale will also have a total of 7,000,000 issuable tokens.
The third ICO offering will run from January 1, 2019 through March 31, 2019. During this offering, Vital Neuro will enter into SAFEs with accredited investors with the price of $5.00 per token and there will be a total of 3,650,000 issuable tokens.
Despite the set dates of the pre-sale’s three offerings, Vital Neuro may extend or shorten them at the company’s own discretion. It will announce any alterations to the pre-sale dates via a press release or another available means of mass communicating.
In a Regulation D Private Sale Non-Token Equity Round prior to the ICO, Vital Neuro had closed $675,000. These proceeds have funded the company’s research and development, allowing it to finish the prototype of its neuroscience-based stress reduction service for enterprise companies.
Alex Doman, the Chief Product Officer of Vital Neuro stated:
“The last two years have been an exciting period of innovation for our team, creating an affordable subscription service that addresses the massive issue of workplace stress and burnout which costs US businesses $30 billion yearly in lost workdays alone. Our exclusive Leonardo Smart Cloud Service powered by AWS, native iOS app, and wireless Vital Smart Headphone provides real time monitoring of biosignals through dry EEG sensors. Vital’s Leonardo is a gamechanger; monitoring stress levels in real time and delivering scientifically designed sound and music through sleek, wireless, high-fidelity headphones, reducing stress in 15-minute sessions personalized to the employee.”
The Neuros Token launch will enable a hard cap of 19,238,500 circulating coins, with investors holding 91.8%. This will leave less than 9% of all outstanding tokens to be retained by Vital Neuro.
Each token correlates to an equal value of Vital Neuro’s equity, pro-rata, which totals 20% of the entire company. If a holder purchases 5,000 or more tokens, they will be eligible to participate in the company’s Discretionary Dividend Program. The Vital Neuro whitepaper provides thorough details on the Neuros Token offering.
Interested to learn more about the latest cryptocurrency news? Check out our news site for news and features on cryptocurrency, blockchain and fintech.